Literature DB >> 8341664

Metastatic conversion of cells by expression of human papillomavirus type 16 E6 and E7 genes.

L Chen1, S Ashe, M C Singhal, D A Galloway, I Hellström, K E Hellström.   

Abstract

The human papillomavirus type 16 (HPV-16) is a DNA tumor virus highly associated with cervical carcinoma. Viral DNA from HPV-16 is found in primary tumors and their metastatic lesions. To investigate the role of HPV-16 oncoproteins in the development of cancer metastasis, the E6 and E7 genes from HPV-16 were inserted into retrovirus and introduced into nonmetastatic mouse cell lines. Expression of either of the viral genes from HPV-16 made the cells metastatic in nude mice. In contrast, expression of the E6 and E7 genes of HPV type 6 (HPV-6b), which is frequently found in nonmalignant HPV-associated diseases, did not. The metastatic ability of cells transduced with viral genes of HPV-16 did not correlate with their growth rate or sensitivity to destruction by natural killer cells. Our results demonstrate that expression of oncogenic proteins of HPV-16 can cause tumor metastasis and implicate HPV-16 in an important role regarding the progression of HPV-associated human cancers.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8341664      PMCID: PMC46964          DOI: 10.1073/pnas.90.14.6523

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Prognostic significance of the presence of human papillomavirus DNA in patients with invasive carcinoma of the cervix.

Authors:  L A King; T Tase; L B Twiggs; T Okagaki; J E Savage; L L Adcock; K A Prem; L F Carson
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

2.  Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms.

Authors:  D Smotkin; H Prokoph; F O Wettstein
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

3.  Human papillomavirus 16 DNA in cervical cancers and in lymph nodes of cervical cancer patients: a diagnostic marker for early metastases?

Authors:  P G Fuchs; F Girardi; H Pfister
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

4.  Prevalence and distribution of human papillomavirus type-16 DNA in pelvic lymph nodes of patients with cervical cancer and in women with no history of cervical abnormality.

Authors:  B R Rose; C H Thompson; L A Chantrill; M H Tattersall; Y E Cossart
Journal:  Int J Cancer       Date:  1992-09-09       Impact factor: 7.396

5.  Differences in the integration pattern and episomal forms of human papillomavirus type 16 DNA found within an invasive cervical neoplasm and its metastasis.

Authors:  D Galehouse; E Jenison; A DeLucia
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

6.  Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16.

Authors:  C Desaintes; S Hallez; P Van Alphen; A Burny
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

7.  The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A.

Authors:  W C Phelps; C L Yee; K Münger; P M Howley
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

8.  The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells.

Authors:  C L Halbert; G W Demers; D A Galloway
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16.

Authors:  L Chen; M T Mizuno; M C Singhal; S L Hu; D A Galloway; I Hellström; K E Hellström
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

10.  Prognostic importance of human papillomavirus type 16 DNA in cervical cancer.

Authors:  F Girardi; P Fuchs; J Haas
Journal:  Cancer       Date:  1992-05-15       Impact factor: 6.860

View more
  7 in total

1.  Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.

Authors:  M W Carroll; W W Overwijk; R S Chamberlain; S A Rosenberg; B Moss; N P Restifo
Journal:  Vaccine       Date:  1997-03       Impact factor: 3.641

2.  SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.

Authors:  Rajesh K Sharma; Abhishek K Srivastava; Esma S Yolcu; Kathryn J MacLeod; Rich-Henry Schabowsky; Shravan Madireddi; Haval Shirwan
Journal:  Vaccine       Date:  2010-07-04       Impact factor: 3.641

3.  Metastatic conversion of chemically transformed human cells.

Authors:  X L Sun; D Li; J Fang; B Casto; I Noyes; G E Milo
Journal:  Gene Expr       Date:  1999

4.  Luciferase activity as a marker of tumor burden and as an indicator of tumor response to antineoplastic therapy in vivo.

Authors:  L Zhang; K E Hellström; L Chen
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

5.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.

Authors:  L Chen; P McGowan; S Ashe; J Johnston; Y Li; I Hellström; K E Hellström
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

6.  Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells.

Authors:  Abdessamad Amine; Sofia Rivera; Paule Opolon; Mehdi Dekkal; Denis S F Biard; Hakim Bouamar; Fawzia Louache; Michael J McKay; Jean Bourhis; Eric Deutsch; Marie-Catherine Vozenin-Brotons
Journal:  PLoS One       Date:  2009-03-26       Impact factor: 3.240

7.  Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors.

Authors:  Y Li; K E Hellstrom; S A Newby; L Chen
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.